EWA
RNAC icon

EverSource Wealth Advisors’s Cartesian Therapeutics RNAC Stock Holding History

EverSource Wealth Advisors’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.71K Buy
548
+295
+117% +$2.19K ﹤0.01% 3219
2026
Q1 		$1.56K Buy
253
+247
+4,117% +$1.76K ﹤0.01% 3720
2025
Q4 		$43 Sell
6
-33
-85% -$267 ﹤0.01% 4180
2025
Q3 		$399 Sell
39
-8
-17% -$90 ﹤0.01% 4006
2025
Q2 		$488 Buy
47
+35
+292% +$373 ﹤0.01% 3907
2025
Q1 		$158 Buy
+12
New +$214 ﹤0.01% 3741

Other funds holding RNAC

FA
Fedenia Advisers Madison, Wisconsin $421M AUM 96.46% 1-Year Est. Return
TFCP
Twin Focus Capital Partners Boston, Massachusetts $983M AUM 37.07% 1-Year Est. Return
MFS
Miller Financial Services Marshall, Michigan $124M AUM 17.62% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
NSIM
North Star Investment Management Chicago, Illinois $1.84B AUM 28.81% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
SCM
Sterling Capital Management Charlotte, North Carolina $5.9B AUM 29.63% 1-Year Est. Return

EverSource Wealth Advisors's RNAC Position: Q2 2026 in Review

EverSource Wealth Advisors increased its Cartesian Therapeutics (RNAC) stake by 117% in Q2 2026, buying an estimated $2.19K and bringing the position to 548 shares worth $5.71K. The position accounts for ﹤0.01% of the portfolio, ranked #3219.

EverSource Wealth Advisors first reported a position in RNAC in Q1 2025 and has held it in 6 quarters since. 17 funds tracked by Wall St. Rank hold RNAC as of Q2 2026.

  • EverSource Wealth Advisors held 548 shares of Cartesian Therapeutics worth $5.71K as of Q2 2026.
  • EverSource Wealth Advisors bought 295 Cartesian Therapeutics shares in Q2 2026, an estimated $2.19K.
  • Cartesian Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #3219 holding.
  • EverSource Wealth Advisors first reported a position in Cartesian Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 17 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.